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Background: The most common indication for cesarean section (CS) in nulliparous women is dystocia secondary
to ineffective myometrial contractility. The aim of this study was to identify a molecular profile in myometrium
associated with dystocic labor.
Methods: Myometrial biopsies were obtained from the upper incisional margins of nulliparous women undergoing
lower segment CS for dystocia (n = 4) and control women undergoing CS in the second stage who had
demonstrated efficient uterine action during the first stage of labor (n = 4). All patients were in spontaneous (non-
induced) labor and had received intrapartum oxytocin to accelerate labor. RNA was extracted from biopsies and
hybridized to Affymetrix HuGene U133A Plus 2 microarrays. Internal validation was performed using quantitative
SYBR Green Real-Time PCR.
Results: Seventy genes were differentially expressed between the two groups. 58 genes were down-regulated in
the dystocia group. Gene ontology analysis revealed 12 of the 58 down-regulated genes were involved in the
immune response. These included (ERAP2, (8.67 fold change (FC)) HLA-DQB1 (7.88 FC) CD28 (2.60 FC), LILRA3 (2.87
FC) and TGFBR3 (2.1 FC)) Hierarchical clustering demonstrated a difference in global gene expression patterns
between the samples from dystocic and non-dystocic labours. RT-PCR validation was performed on 4 genes ERAP2,
CD28, LILRA3 and TGFBR3
Conclusion: These findings suggest an underlying molecular basis for dystocia in nulliparous women in
spontaneous labor. Differentially expressed genes suggest an important role for the immune response in dystocic
labor and may provide important indicators for new diagnostic assays and potential intrapartum therapeutic
targets.
Background
As cesarean section (CS) rates continue to rise through-
out the developed world, an improved understanding of
the molecular mechanisms underlying parturition at
term is urgently required. Between 1974 and 2008 over-
all cesarean rates increased from 5% to 19.1% in the
National Maternity Hospital (NMH), Dublin and one of
the major contributors to this was a 4-fold increase in
cesarean deliveries amongst term singleton cephalic nul-
liparas (TSCN) [1]. CS rates vary between institutions,
although TSCN CS rates correlate with institutional CS
rates and we have previously documented that 98% of
inter-institutional variation in overall CS rates can be
attributed to TSCN rates [2], which demonstrates that
TSCN as a cohort has a significant impact on cesarean
rates within any obstetric population. However, despite
much attention within the obstetric literature addressing
the timing and mode of twin deliveries [3], vaginal
breech delivery [4] and the optimum management of
pre-term, growth-restricted fetuses [5], little emphasis
has been placed on the management of TSCN, an
important group of parturients, which has been rela-
tively neglected hitherto by research initiatives [2].
The most common primary indication for CS is dysto-
cia or slow labor, most commonly secondary to ineffi-
cient myometrial contractility. Dystocia is a common
obstetric problem, affecting 3-8% of deliveries [6], and is
a particular complication of first pregnancies. In
* Correspondence: Colm.oherlihy@ucd.ie
3UCD School of Medicine and Medical Science, Dublin, Ireland
Full list of author information is available at the end of the article
Brennan et al. BMC Pregnancy and Childbirth 2011, 11:74
http://www.biomedcentral.com/1471-2393/11/74
© 2011 Brennan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.approximately 40% of first labors, dystocia can be ade-
quately and safely corrected by intrapartum administra-
tion of oxytocin, resulting in vaginal delivery [7]. In 10-
20% of cases of dystocia, however, myometrial response
to oxytocin is poor and CS becomes the only safe option
following prolonged labor [8]. It is believed this compli-
cation is likely to increase mainly due to delayed child-
bearing and increased prevalence of obesity in the
obstetric population both factors which adversely affect
intrapartum myometrial contractility [9,10]. For every
1% increase in the incidence of nulliparous CS for dys-
tocia, overall caesarean rates will inevitably increase by
at least 0.5% due to the consequent increase in CS in
women with scarred uteri. An improved understanding
of the molecular mechanisms underlying dystocic labor
and may result in alternative adjuvants to oxytocin.
To date, we are not aware of studies using gene expres-
sion profiling to evaluate the physiology and mechanisms
underlying dystocia in nulliparous women in spontaneous
labor. In a large Swedish population-based study, which
examined over two million deliveries, Algovik et al
demonstrated a large genetic influence on dystocia [6].
This study estimated that heritability contributed 28% in
the liability of developing primary dystocia, with significant
concordance evident amongst monozygotic twins and an
increased risk of dystocia in women who had a mother or
sister with a history of dystocic labors. Additionally, trans-
genic knockout mouse models examining prostaglandin
F2a receptor [11] and testosterone 5-a-reductase type 1
[12], respectively, exhibit an absence of parturition,
although screening for mutations in these candidate dysto-
cia-related genes in humans proved unsuccessful [13]. The
genetic basis of dystocia is likely to be more complex that
a single gene mutation. Considering the clinical impact of
dystocia, a single gene mutation would be subject to puri-
fying selection and would be selected against in the evolu-
tionary process. Therefore genome-wide screening should
provide more useful insights. The aim of this study was to
use gene expression microarrays to examine the temporal
and spatial changes in myometrial gene expression during
normally-progressing and dystocic labors to improve our
understanding of the molecular mechanisms underlying
term dystocic labor.
Methods
The National Maternity Hospital is a tertiary referral
university institution that publishes an Annual Clinical
Report, which includes detailed analysis of obstetric out-
comes and modes of delivery of all delivered mothers (>
9, 000 annually) and on all perinatal deaths (stillbirths
and first-week neonatal deaths of infants who weighed >
500 g, corrected for the exclusion of lethal malforma-
tions). Management of nulliparous labor has been stan-
dardized in the institution throughout the last four
decades according to an Active Management of Labor
protocol [8], the principles of which include accurate
early diagnosis of labor, early correction of inefficient
uterine action, and one to one care by a personal nurse
throughout labor [14]. Inefficient uterine action is cor-
rected by the administration of intravenous oxytocin in
a concentration of 10 IU/L, when subsequent cervical
dilatation does not progress at a rate of at least 1 cm
per hour. Oxytocin acceleration is commenced in a
dosage of 5 mU/min, and is increased to a maximum of
30 mU/min and titrated against the frequency of uterine
contractions, which are restricted to 7 contractions in
15 minutes. Progress in all labors is recorded on an
individual partogram, which plots cervical dilatation as a
function of time, up to a maximum of 12 hours (Figure
1). Using this protocol, less than 3% of women admitted
to the NMH remain undelivered after 12 hours, when
they are delivered by CS unless delivery is imminent.
Definitions used for this study included: nulliparous:
para 0, irrespective of gravidity; term: greater than or
equal to 37 completed weeks gestation and singleton
gestation, no evidence of a multiple gestation after the
first trimester. Representative partograms for both
groups used in this study are shown in Figure 1.
Sample Collection
Patients provided informed consent to partake in this
study and ethical approval was obtained from ethics
committee in the National Maternity Hospital, Holles
Street, Ireland. Myometrial biopsies were obtained from
the midpoint of the upper incisional margins of the
uteri of women undergoing lower segment CS for dysto-
cia (n = 4) and in control women undergoing CS in the
second stage, who had demonstrated efficient (≥ 1c m
dilatation per hour) uterine action (EUA) during the
first stage of labor (n = 4). Care was taken to remove
decidual tissue. All patients in this group underwent CS
for persistent occiput posterior position. A scissors was
used to obtain myometrial samples, all of which mea-
sured approximately 1 cm
3. All patients presented to the
labor ward in spontaneous labor with intact membranes
and subsequently underwent an amniotomy and intra-
partum oxytocin acceleration. All amniotomies were
performed at a cervical dilatation of 3 cm or less.
Patient characteristics are outlined in table 1; all were
Caucasian with singleton pregnancies, aged less than 35
years. No women developed pyrexia during labor or
received prophylactic antibiotics.
Myometrial samples were transferred directly in the
operating room into RNALater (Qiagen, Crawley, West
Sussex, UK) and stored at 4°C for 24 hours. RNALater was
then removed and samples were stored at -80°C. Total
RNA extraction and purification from tissue samples were
carried out using TRIzol reagent (Invitrogen, Carlsbad,
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labeled complementary RNA and hybridization to
HGU133 Plus 2.0 GeneChips (Affymetrix, Santa Clara,
CA) was performed as per the manufacturer’sr e c o m -
mended protocol.
Data Analysis
Raw data (cel files) were analyzed using Bioconductor
1.9 http://bioconductor.org running on R 2.6.0 [15].
Normalization was performed using the Affymetrix
package’s Robust Multichip Average (RMA) default
method [16]. Differential gene expression was measured
using a modified t test, and genes demonstrating greater
than 2 fold difference and a p value < 0.05 were consid-
ered to be differentially expressed. Hierarchical cluster-
ing and principal components analysis were performed
using MatLab 7 (MathWorks, Apple Hill Drive, MA).
Raw data are available in Geo http://www.ncbi.nlm.nih.
gov/projects/geo/, accession number GSE32178.
Quantitative SYBR Green Real-Time PCR
Total RNA was isolated from tissues using Trizol (Invitro-
gen) and reverse transcribed using SuperScript II™
Reverse Transcriptase (Invitrogen) according to the
manufacturer’s instructions. ERAP2 (FW-TGGATGG-
GACCAACTCATTACA, RV- TGCACCAACTAGCTGA
AACAC), CD28 (FW- GGCATCCCTTCACAAAGGACT,
RV- CCCCGTTTTTGAGTAAACCTGA), LILRA3 (FW-
CCAGTGTGTTTCTGATGTCAGC, RV- CCGGATG-
CACCGAGATGAAG), HLA-DQB1 (FW- AGGGT-
GAATGTTTCCCCCTC, RV- CTGCCTGGGTAGA
AATCCGT) primers were designed using Primer Express
software (Applied Biosystems Version 2.0) and used to
amplify specific DNA fragments with SYBR Green PCR
Master Mix (Applied Biosystems) using a 7900HT Fast
Real-Time PCR System (Applied Biosystems). Relative
expression levels were calculated using the qBase real-time
PCR relative quantification software [17] with all samples
normalized to GAPDH expression. Negative controls
included a no template control and a no reverse transcrip-
tase control. All qRT-PCR reactions were performed in
triplicate.
Results
Genome-wide transcriptomic analysis was performed on
myometrial biopsies taken from the lower uterine seg-
ment in Caucasian women undergoing CS for dystocia
(n = 4) and in women who demonstrated efficient
Figure 1 Dystocia and Efficient Uterine Action. Partograms representing dystocia and efficient uterine action.
Table 1 Patient characteristics







Dystocia 29 22.8 0 40
+3 10hrs Yes 2 cm 3810 gm
Dystocia 26 24.4 0 41
+0 11hrs Yes 4 cm 4260 gm
Dystocia 33 22.7 0 41
+1 9hrs Yes 2 cm 2890 gm
Dystocia 27 31.2 0 41
+1 6hrs Yes 3 cm 3710 gm
EUA 25 23.4 0 40
+6 10hrs Yes 10 cm 3145 gm
EUA 31 24.3 0 40
+5 6hrs Yes 10 cm 3440 gm
EUA 32 28.7 0 39
+3 8hrs Yes 10 cm 3930 gm
EUA 30 31.0 0 41
+5 8hrs30min Yes 10 cm 4840 gm
Abbreviations: EUA - efficient uterine action, BMI - body mass index (at booking).
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a second stage CS for persistent occiput posterior posi-
tion. All of the patients included in the study were nulli-
paras in spontaneous labor between 37 and 42 weeks.
There were no differences between the two groups
regarding maternal age, BMI, or gestation at delivery
(Table 1). The mean birthweight in the dystocic group
was 3667 gm compared to 3839 gm in the efficient uter-
ine action group; all patients received epidural
anaesthesia.
Unsupervised hierarchical clustering and principal
components analysis (PCA) were performed to gain a
global view of gene expression in dystocia and efficient
myometrium. Probes were filtered based on gene
entropy and genes displaying entropy values below the
10
th centile were removed prior to hierarchical cluster-
ing and PCA. As demonstrated in Figure 2, hierarchical
clustering of genes with a high entropy value produced
a very distinctive separation between dystocia and EUA.
This was confirmed using PCA whereby the four dys-
tocic samples clustered together (Figure 2b), demon-
strating that dystocia has a distinctive myometrial
molecular profile compared to normally progressing
labor.
Figure 2 Molecular Profile of Dytocia. Hierarchical clustering demonstrating a distinct dystocia transcriptomic profile (a). Principal components
analysis demonstrating aggregation of dystocia specimens.
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detail, both dystocic and non-dystocic groups were com-
pared to identify differentially expressed genes. Given
the relatively small number of samples in both groups,
strict thresholds were applied and only genes that exhib-
i t e da2 - f o l dc h a n g ea n dapv a l u e<0 . 0 5w e r ec o n s i d -
ered differentially expressed( F i g u r e3 a ) .U s i n gt h i s
threshold, 70 genes were differentially expressed in
women with dystocia compared to efficient uterine
action (Table 2). Within the 70 genes, 58 were down-
regulated and 12 were up-regulated in the dystocic spe-
cimens compared to normally progressing labor. Gene
ontology analysis revealed that the most common pro-
cesses in the differentially expressed genes were immune
response, transcription and DNA replication (Figure 3b).
In particular a number of key regulators of the cell cycle
Figure 3 Differentially Expressed Genes. Volcano plot demonstrating differentially expressed genes (a). Gene ontology analysis of differentially
expressed genes (b)
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Gene Symbol Gene Title Fold Change p value
ERAP2 endoplasmic reticulum aminopeptidase 2 -8.67 0.0009
C15orf48 chromosome 15 open reading frame 48 -8.11 0.0732
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 -7.88 0.0079
LOC389831 hypothetical gene supported by AL713796 -6.35 0.0503
HBG1 hemoglobin, gamma A -5.05 0.0062
LOC389831 hypothetical gene supported by AL713796 -4.75 0.0406
CCNE2 cyclin E2 -3.71 0.0028
KIAA0101 KIAA0101 -3.66 0.0253
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein -3.08 0.0043
C7 complement component 7 -2.87 0.0217
LILRA3 leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3 -2.84 0.0916
TRIM13 tripartite motif-containing 13 -2.74 0.0744
MLF1IP MLF1 interacting protein -2.68 0.0400
DTL denticleless homolog (Drosophila) -2.60 0.0009
CD28 CD28 molecule -2.60 0.0576
LOC283788 FSHD region gene 1 pseudogene -2.60 0.0195
TFCP2L1 transcription factor CP2-like 1 -2.56 0.0862
RRM2 ribonucleotide reductase M2 -2.55 0.0177
EVI2A ecotropic viral integration site 2A -2.51 0.0926
TYMS thymidylate synthetase -2.51 0.0323
EAF2 ELL associated factor 2 -2.47 0.0937
ZNF367 zinc finger protein 367 -2.46 0.0018
MCM4 minichromosome maintenance complex component 4 -2.43 0.0083
MCM10 minichromosome maintenance complex component 10 -2.43 0.0527
KLF5 Kruppel-like factor 5 (intestinal) -2.41 0.0665
CENPK centromere protein K -2.40 0.0656
HELLS helicase, lymphoid-specific -2.39 0.0190
CDC6 cell division cycle 6 homolog (S. cerevisiae) -2.37 0.0798
TYMS thymidylate synthetase -2.30 0.0178
GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) -2.29 0.0473
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 -2.28 0.0648
MRPL43 mitochondrial ribosomal protein L43 -2.26 0.0089
HAMP hepcidin antimicrobial peptide -2.26 0.0816
MCM2 minichromosome maintenance complex component 2 -2.25 0.0099
GAPT GRB2-binding adaptor protein, transmembrane -2.24 0.0757
RRAGD Ras-related GTP binding D -2.22 0.0683
TREM2 triggering receptor expressed on myeloid cells 2 -2.20 0.0921
PBK PDZ binding kinase -2.18 0.0865
SVEP1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 -2.17 0.0733
TGFBR3 transforming growth factor, beta receptor III -2.16 0.0155
PPAP2A phosphatidic acid phosphatase type 2A -2.15 0.0684
UHRF1 ubiquitin-like with PHD and ring finger domains 1 -2.14 0.0738
TFEC transcription factor EC -2.14 0.0551
PLEKHG1 pleckstrin homology domain containing, family G (with RhoGef domain) member 1 -2.14 0.0874
ZWILCH Zwilch, kinetochore associated, homolog (Drosophila) -2.13 0.0400
SPA17 sperm autoantigenic protein 17 -2.12 0.0464
STK17B serine/threonine kinase 17b -2.12 0.0461
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) -2.12 0.0324
MAFIP MAFF interacting protein -2.10 0.0154
BUB1B budding uninhibited by benzimidazoles 1 homolog beta (yeast) -2.10 0.0420
RRM2 ribonucleotide reductase M2 -2.10 0.0415
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Page 6 of 10were down-regulated in the dystocic samples such as
cyclin E, CENPK and ID2, all of which promote progres-
sion through the cell cycle.
As the majority of dystocia-related genes were down-
regulated, these genes were examined in detail. A sig-
nificant proportion of genes in this group were asso-
ciated with inflammation and immune response. To
validate our findings, qRT-PCR was performed on four
of the immune response genes: ERAP2 and HLA-
DQB1, both of which play key roles in antigen presen-
tation; CD28, a key regulator of the TH2 T cell
response and LILRA3, a regulator of monocyte and B
cell activation. qRT-PCR confirmed that all four genes
were down-regulated in dystocia compared to normally
progressing labor (Figure 4).
Discussion
Although dystocia represents one of the major indica-
tions for primary CS, to our knowledge, genome-wide
analysis has not been applied to the study of the mole-
cular mechanisms underlying dystocia in term nullipar-
ous labor. High-throughput screening technologies, such
as DNA microarrays have been used to improve com-
prehension of the major structural and metabolic trans-
formations, which affect the myometrium from the very
beginning of pregnancy until the onset of labor [18-22].
Changes in the structural and contractile genes asso-
ciated with the actin cytoskeleton, focal adhesion mole-
cules, adherens and tight junctions represent a large
subset of genes that are over-expressed in pregnant,
compared to non-pregnant, human myometrium [18].
Additionally, in an attempt to further decipher the
causes of pre-term labor, a number of investigators have
used transcriptomic approaches to examine the transi-
tion from uterine quiescence to the onset of contrac-
tions in small numbers of patients [18-22]. These
studies identified a number of genes, which may be use-
ful in predicting pre-term labor; however, none have
specifically examined dystocia. Our findings demonstrate
significant differences in the myometrial transcriptomic
profiles of dystocic as compared to normally-progressing
labors. In particular, we have demonstrated that a num-
ber of key regulators of the host immune response are
down-regulated in dystocia.
The strengths of this study are mainly based around
the study design whereby the inclusion criteria were
strict. Patients included in this study were nulliparas in
spontaneous labor. All women in the dystocia group
received 30mU/min oxytocin for at least 4 hours. In
addition the study was performed in a unit where the
diagnosis and management of spontaneous nulliparous
labor has been standardized for the last four decades
[14]. A major weakness of this study is the small num-
ber of samples studied. In addition, sampling the lower
segment alone may give a true global description of the
dystocic transcriptome. Transcriptomic profiling has
shown different myometrial gene expression patterns in
lower segment compared to fundal biopsies in labour
[22,23], however the majority of these studies appear to
have been performed in multiparous patients and thus
these finds may not be applicable to our study. Dystocia,
due to ineffective myometrial contractility is much more
common in women undergoing induction of labor,
although induced labors were specifically excluded from
Table 2 Differentially expressed genes in dystocic labor (Continued)
BHLHE41 basic helix-loop-helix family, member e41 -2.07 0.0126
MCM5 minichromosome maintenance complex component 5 -2.06 0.0305
ATP8B1 ATPase, aminophospholipid transporter, class I, type 8B, member 1 -2.05 0.0653
UBE2T ubiquitin-conjugating enzyme E2T (putative) -2.05 0.0358
ATAD2 ATPase family, AAA domain containing 2 -2.03 0.0980
OXR1 oxidation resistance 1 -2.02 0.0456
EZR ezrin -2.00 0.0416
PPAP2A phosphatidic acid phosphatase type 2A 2.04 0.0741
AQP3 aquaporin 3 (Gill blood group) 2.06 0.0844
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 2.08 0.0582
GIN1 gypsy retrotransposon integrase 1 2.11 0.0373
RGS17 regulator of G-protein signaling 17 2.12 0.0074
LOC642236 similar to FRG1 protein (FSHD region gene 1 protein) 2.13 0.0203
ITGB3BP integrin beta 3 binding protein (beta3-endonexin) 2.22 0.0323
POPDC3 popeye domain containing 3 2.28 0.0289
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 2.28 0.0350
LOC253039 hypothetical LOC253039 2.51 0.0832
PRIM1 primase, DNA, polypeptide 1 (49kDa) 2.55 0.0039
CLDN10 claudin 10 3.30 0.0988
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groups. Also the indication for induction is important as
a woman undergoing labor induction following a pro-
longed interval of ruptured membranes is likely to have
a different myometrial profile to a patient being induced
for pre-eclampsia. The absence of an independent vali-
dation cohort represents another weakness of this study,
although internal validation using rt-PCR was performed
to address this issue.
This study further strengthens the potential argument
for an underlying genetic predisposition for dystocia
[6,24]. The finding that the majority of differentially
expressed genes were down-regulated suggests that
many of these may harbour loss-of-function mutations.
The association of dystocia with an impaired immune
response is also in agreement with a larger recent study
by Mittal et al [25], who demonstrated increased expres-
sion of a number of inflammatory genes in patients with
arrest of descent in the second stage, a cohort similar to
the efficient uterine action group in our study. Compari-
son of our findings to those of Mittal et al [25] should
be tempered by the fact that their study did not stratify
for parity or mode of onset of labor. The importance of
the inflammatory response in spontaneous labor cannot
be overstated, since Unal et al [26] recently demon-
strated that maternal inflammatory markers increase
before the onset of spontaneous labor, suggesting that
any future studies of dystocia should be stratified
according to labor onset (spontaneous versus induced).
Similarly, dystocia in a multiparous woman is much
more likely to be secondary to obstruction than ineffi-
cient uterine action and thus likely to have a different
Figure 4 PCR validation. rt-PCR based validation of 4 immune related genes
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stratification by parity.
The identification of ERAP2 as a gene that was signifi-
cantly down-regulated in dystocia is of particular inter-
est because ERAP2 has been identified as a genetic
susceptibility locus for preeclampsia in a number of dif-
ferent populations [27,28]. Although ERAP2 is consid-
ered to be a member of the oxytocinase subfamily of
M1 aminopeptidases, it has no hydrolytic activity
towards oxytocin [29]. ERAP2 which is regulated by
interferon gamma appears to play a key role in the
innate immune response whereby it trims various N-
terminal extended precursors to major histocompatibil-
ity complex class I-presented antigenic peptides [29].
Although a number of missense single nucleotide poly-
morphisms (SNP) in ERAP2 have been associated with
an increased risk of preeclampsia [27,28], the functional
importance of these SNPs is still not fully understood. A
recent study did however demonstrate that specific
ERAP2 haplotypes are associated with lower levels of
MHC class I expressed on the surface of B cells, sug-
gesting that naturally occurring ERAP2 deficiency affects
MHC presentation and immune response [30].
Although historical studies have suggested that labor
may be easier to induce in preeclamptic patients [31,32],
a number of recent reports have suggested that women
with preeclampsia undergoing labor induction have
higher cesarean delivery rates compared with non-pree-
clamptics, independent of parity or gestational age
[33-35]. In a large retrospective cohort study, Kim et al
demonstrated a significantly higher term nulliparous CS
rate in induced preeclamptic patients compared to
healthy controls [33]. While our study was conducted
on nulliparas in spontaneous term labour these findings
raise intriguing questions about the role of ERAP2 and
efficient uterine action in preeclamptic patients, which
warrant further investigation.
Conclusion
Our study demonstrates an obvious difference in the
myometrial transcriptomic profiles in women with dys-
tocia and efficient uterine action but it also raises a
number of questions. It is currently not possible to pre-
dict which women will develop dystocia before the
onset of spontaneous labor. Due to the invasive nature
of a biopsy, it would not be possible to reduce a myo-
metrial profile to clinical utility, but it is worth noting
that two of the genes significantly down-regulated in
dystocic patients, ERAP2 and LILRA3, code for secreted
proteins which could potentially be detected in human
plasma. LILRA3 has previously been detected in rheu-
matoid arthritis [36]. Nevertheless, the advent of whole
genome sequencing offers a platform to further investi-
gate dystocia and to identify the genetic determinants of
this complex condition, which is central to ever-increas-
ing international CS rates and thus represents a major
current public health issue.
Funding
The study was funded by the National Maternity Hospi-
tal Research Fund
Author details
1National Maternity Hospital, Dublin , Ireland.
2UCD School of Biomolecular
and Biomedical Science, UCD Conway Institute, Dublin , Ireland.
3UCD
School of Medicine and Medical Science, Dublin, Ireland.
Authors’ contributions
DJB conceived the study, collected the samples, performed statistical
analysis and drafted the manuscript, SMG processed the samples and
performed RT-PCR, ER performed statistical analysis, DOC performed RT-PCR,
MR conceived the study, provided samples and drafted the manuscript, COH
conceived the study, provided the samples and drafted the manuscript. All
authors read and approved the final manuscript.
Authors information
DJB, MR and COH are obstetricians and gynaecologists. DJB, SMG, ER and
DOC are research scientists with an interest in biomarker identification and
validation
Competing interests
The authors declare that they have no competing interests.
Received: 11 August 2011 Accepted: 16 October 2011
Published: 16 October 2011
References
1. Brennan DJ, Murphy M, Robson MS, O’Herlihy C: The singleton, cephalic,
nulliparous woman after 36 weeks of gestation: contribution to overall
cesarean delivery rates. Obstet Gynecol 2011, 117(2 Pt 1):273-279.
2. Brennan DJ, Robson MS, Murphy M, O’Herlihy C: Comparative analysis of
international cesarean delivery rates using 10-group classification
identifies significant variation in spontaneous labor. Am J Obstet Gynecol
2009, 201(3):308-e301, 308.
3. Lee YM, Wylie BJ, Simpson LL, D’Alton ME: Twin chorionicity and the risk
of stillbirth. Obstet Gynecol 2008, 111(2 Pt 1):301-308.
4. Hannah ME, Hannah WJ, Hewson SA, Hodnett ED, Saigal S, Willan AR:
Planned caesarean section versus planned vaginal birth for breech
presentation at term: a randomised multicentre trial. Term Breech Trial
Collaborative Group. Lancet 2000, 356(9239):1375-1383.
5. Riskin A, Riskin-Mashiah S, Bader D, Kugelman A, Lerner-Geva L, Boyko V,
Reichman B: Delivery mode and severe intraventricular hemorrhage in
single, very low birth weight, vertex infants. Obstet Gynecol 2008,
112(1):21-28.
6. Algovik M, Nilsson E, Cnattingius S, Lichtenstein P, Nordenskjold A,
Westgren M: Genetic influence on dystocia. Acta Obstet Gynecol Scand
2004, 83(9):832-837.
7. Cahill DJ, Boylan PC, O’Herlihy C: Does oxytocin augmentation increase
perinatal risk in primigravid labor? Am J Obstet Gynecol 1992,
166(3):847-850.
8. O’Driscoll K, Jackson RJ, Gallagher JT: Prevention of prolonged labour. Br
Med J 1969, 2(5655):477-480.
9. Lynch CM, Sexton DJ, Hession M, Morrison JJ: Obesity and mode of
delivery in primigravid and multigravid women. Am J Perinatol 2008,
25(3):163-167.
10. Treacy A, Robson M, O’Herlihy C: Dystocia increases with advancing
maternal age. American journal of obstetrics and gynecology 2006,
195(3):760-763.
11. Sugimoto Y, Yamasaki A, Segi E, Tsuboi K, Aze Y, Nishimura T, Oida H,
Yoshida N, Tanaka T, Katsuyama M, et al: Failure of parturition in mice
lacking the prostaglandin F receptor. Science 1997, 277(5326):681-683.
Brennan et al. BMC Pregnancy and Childbirth 2011, 11:74
http://www.biomedcentral.com/1471-2393/11/74
Page 9 of 1012. Mahendroo MS, Cala KM, Landrum DP, Russell DW: Fetal death in mice
lacking 5alpha-reductase type 1 caused by estrogen excess. In Molecular
endocrinology. Volume 11. Baltimore, Md; 1997:(7):917-927.
13. Algovik M, Lagercrantz J, Westgren M, Nordenskjold A: No mutations
found in candidate genes for dystocia. In Human reproduction. Volume 14.
Oxford, England; 1999:(10):2451-2454.
14. O’Driscoll K, Meagher D, Robson M: The active management of labor. New
York: Mosby Year Book Limited; 2004.
15. Team RDC: A language and environment for statistical computing. R
Foundation for Statistical Computing 2008.
16. Gautier L, Cope L, Bolstad BM, Irizarry RA: affy–analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 2004, 20(3):307-315.
17. Dolle L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V,
Hondermarck H: Nerve growth factor receptors and signaling in breast
cancer. Curr Cancer Drug Targets 2004, 4(6):463-470.
18. Breuiller-Fouche M, Germain G: Gene and protein expression in the
myometrium in pregnancy and labor. In Reproduction. Volume 131.
Cambridge, England; 2006:(5):837-850.
19. Esplin MS, Fausett MB, Peltier MR, Hamblin S, Silver RM, Branch DW,
Adashi EY, Whiting D: The use of cDNA microarray to identify
differentially expressed labor-associated genes within the human
myometrium during labor. American journal of obstetrics and gynecology
2005, 193(2):404-413.
20. Havelock JC, Keller P, Muleba N, Mayhew BA, Casey BM, Rainey WE,
Word RA: Human myometrial gene expression before and during
parturition. Biology of reproduction 2005, 72(3):707-719.
21. Charpigny G, Leroy MJ, Breuiller-Fouche M, Tanfin Z, Mhaouty-Kodja S,
Robin P, Leiber D, Cohen-Tannoudji J, Cabrol D, Barberis C, et al: A
functional genomic study to identify differential gene expression in the
preterm and term human myometrium. Biology of reproduction 2003,
68(6):2289-2296.
22. Bukowski R, Hankins GD, Saade GR, Anderson GD, Thornton S: Labor-
associated gene expression in the human uterine fundus, lower
segment, and cervix. PLoS medicine 2006, 3(6):e169.
23. Havelock J, Keller P, Muleba N, Mayhew B, Casey B, Rainey W, Word R:
Human myometrial gene expression before and during parturition.
Biology of reproduction 2005, 72(3):707-719.
24. Berg-Lekås ML, Högberg U, Winkvist A: Familial occurrence of dystocia.
Am J Obstet Gynecol 1998, 179(1):117-121.
25. Mittal P, Romero R, Tarca AL, Draghici S, Nhan-Chang CL,
Chaiworapongsa T, Hotra J, Gomez R, Kusanovic JP, Lee DC, et al: A
molecular signature of an arrest of descent in human parturition. Am J
Obstet Gynecol 2011, 204(2):177-e115, 133.
26. Unal ER, Cierny JT, Roedner C, Newman R, Goetzl L: Maternal inflammation
in spontaneous term labor. Am J Obstet Gynecol 2011, 204(3):223-e221,
225.
27. Johnson MP, Roten LT, Dyer TD, East CE, Forsmo S, Blangero J,
Brennecke SP, Austgulen R, Moses EK: The ERAP2 gene is associated with
preeclampsia in Australian and Norwegian populations. Hum Genet 2009,
126(5):655-666.
28. Hill LD, Hilliard DD, York TP, Srinivas S, Kusanovic JP, Gomez R, Elovitz MA,
Romero R, Strauss JF: Fetal ERAP2 variation is associated with
preeclampsia in African Americans in a case-control study. BMC Med
Genet 2011, 12(1):64.
29. Tanioka T, Hattori A, Masuda S, Nomura Y, Nakayama H, Mizutani S,
Tsujimoto M: Human leukocyte-derived arginine aminopeptidase. The
third member of the oxytocinase subfamily of aminopeptidases. J Biol
Chem 2003, 278(34):32275-32283.
30. Andres AM, Dennis MY, Kretzschmar WW, Cannons JL, Lee-Lin SQ, Hurle B,
Schwartzberg PL, Williamson SH, Bustamante CD, Nielsen R, et al: Balancing
selection maintains a form of ERAP2 that undergoes nonsense-mediated
decay and affects antigen presentation. PLoS Genet 2010, 6(10):e1001157.
31. Taylor ES, Bruns PD, Anker RM, Drose VE: Correlation of urinary estrogen-
pregnanediol excretion with uterine motility during pregnancy. Am J
Obstet Gynecol 1955, 70(4):894-909.
32. Zuspan FP, Talledo E: Factors affecting delivery in eclampsia: the
condition of the cervix and uterine activity. Am J Obstet Gynecol 1968,
100(5):672-685.
33. Kim LH, Cheng YW, Delaney S, Jelin AC, Caughey AB: Is preeclampsia
associated with an increased risk of cesarean delivery if labor is
induced? J Matern Fetal Neonatal Med 2010, 23(5):383-388.
34. Ben-Haroush A, Yogev Y, Glickman H, Kaplan B, Hod M, Bar J: Mode of
delivery in pregnant women with hypertensive disorders and
unfavorable cervix following induction of labor with vaginal application
of prostaglandin E. Acta Obstet Gynecol Scand 2005, 84(7):665-671.
35. Xenakis EM, Piper JM, Field N, Conway D, Langer O: Preeclampsia: is
induction of labor more successful? Obstetrics and gynecology 1997,
89(4):600-603.
36. An H, Chandra V, Piraino B, Borges L, Geczy C, McNeil HP, Bryant K, Tedla N:
Soluble LILRA3, a potential natural antiinflammatory protein, is increased
in patients with rheumatoid arthritis and is tightly regulated by
interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. J
Rheumatol 2010, 37(8):1596-1606.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2393/11/74/prepub
doi:10.1186/1471-2393-11-74
Cite this article as: Brennan et al.: Identification of a myometrial
molecular profile for dystocic labor. BMC Pregnancy and Childbirth 2011
11:74.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Brennan et al. BMC Pregnancy and Childbirth 2011, 11:74
http://www.biomedcentral.com/1471-2393/11/74
Page 10 of 10